Marksans Pharma gets USFDA approval for synthetic Vitamin D tablets

vitaminMarksans Pharma Ltd said the United States Food & Drug Administration has given its approval for its paricalcitol capsules — a synthetic equivalent of Vitamin D.

Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in the body. Paricalcitol Capsules are therapeutically equivalent to the reference listed drug Zemplar Capsules of Abbvie Inc.

Paricalcitol is used to treat or prevent hyper parathyroidism (overactive para thyroid gland), especially in those with kidney problems. It has been used to reduce parathyroid hormone level.

An Abbreviated New Drug Application (ANDA) is an application for a U.S. generic drug approval for an existing licensed medication or approved drug.

Marksans Pharma, headquartered at Mumbai, India, was founded in 2001 and is a global pharmaceutical company engaged in R&D and offer Contract Research And Manufacturing Services (CRAMS) to international pharmaceutical organizations.

The company deals in Over-the-counter (OTC) & prescription drugs which have wide ranging applications crosswise the fields such as Oncology, Gastroenterology, Gynaecology, Cardiovascular, antibiotics, antidiabetic, pain management and among others.

Mark Saldanha is the founder promoter of the company.